|
|
|
Volumn 2, Issue 2, 2004, Pages 107-113
|
|
Update on monoclonal antibody therapy in chronic lymphocytic leukemia.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALEMTUZUMAB;
ANTIIDIOTYPIC ANTIBODY;
CANCER ANTIBODY;
LEUKOCYTE ANTIGEN;
MONOCLONAL ANTIBODY;
RITUXIMAB;
TUMOR ANTIGEN;
TUMOR PROTEIN;
ANIMAL;
ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY;
AUTOIMMUNE DISEASE;
CHRONIC LYMPHATIC LEUKEMIA;
DISEASE COURSE;
DISEASE MANAGEMENT;
DRUG RESISTANCE;
HUMAN;
IMMUNOLOGY;
IMMUNOTHERAPY;
LEUKOPENIA;
MOUSE;
RAT;
REVIEW;
RISK;
TUMOR LYSIS SYNDROME;
ANIMALS;
ANTIBODIES, ANTI-IDIOTYPIC;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, NEOPLASM;
ANTIBODY-DEPENDENT CELL CYTOTOXICITY;
ANTIGENS, CD;
ANTIGENS, NEOPLASM;
AUTOIMMUNE DISEASES;
DISEASE MANAGEMENT;
DISEASE PROGRESSION;
DRUG RESISTANCE, NEOPLASM;
HUMANS;
IMMUNOTHERAPY;
LEUKEMIA, LYMPHOCYTIC, CHRONIC;
LEUKOPENIA;
MICE;
NEOPLASM PROTEINS;
RATS;
RISK;
TUMOR LYSIS SYNDROME;
|
|
EID: 34548602963
PISSN: 15430790
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (4)
|
|
References (111)
|
